← Back to Search

Thermal Ablation

NanoTherm Ablation for Prostate Cancer

N/A
Waitlist Available
Research Sponsored by MagForce USA
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 months (+/- 1 month)
Awards & highlights

Summary

This trial evaluates NanoTherm ablation, a treatment that uses tiny particles to heat and destroy small cancerous areas in the prostate. It targets patients with intermediate-risk prostate cancer who have small lesions in Gleason 3+4 disease. The treatment aims to offer a less invasive option compared to traditional methods like surgery or radiation, by using heat to kill cancer cells in a very targeted area. NanoTherm ablation uses magnetic nanoparticles to heat and destroy cancer cells, a method that has shown feasibility and good tolerability in recent clinical trials.

Eligible Conditions
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 months (+/- 1 month)
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 months (+/- 1 month) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Rate of Ablation Success
Secondary study objectives
Adverse Event Rate

Trial Design

1Treatment groups
Experimental Treatment
Group I: Ablation ArmExperimental Treatment1 Intervention
Subjects in this arm of the study will have focal ablation of the prostate cancer lesion with the NanoTherm technology. This ablation will be followed-up transperineal prostate biopsy at 4 months after treatment.

Find a Location

Who is running the clinical trial?

MagForce USALead Sponsor
1 Previous Clinical Trials
100 Total Patients Enrolled
David Hammond, MSStudy DirectorMagForce USA
~1 spots leftby Oct 2025